RP3
Phase 1Biologic
RP3 is one of 15 biologic programs targeting Solid Tumours. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Solid Tumours
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Gemzar
Johnson & JohnsonPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Hernexeos
Boehringer IngelheimPhase 2
Adriamycin
PfizerPhase 1
Cetrelimab
Johnson & JohnsonPhase 2
HMBD-001
HHummingbird Bioscience
Phase 2
AZD0171
AstraZenecaPhase 2
Dose Expansion
PPeking University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- RReplimune Inc.